Your browser doesn't support javascript.
loading
Finding synergies for the 3Rs - Repeated Dose Toxicity testing: Report from an EPAA Partners' Forum.
Laroche, Charles; Annys, Erwin; Bender, Hans; Botelho, Danielle; Botham, Phil; Brendler-Schwaab, Susanne; Clayton, Rick; Corvaro, Marco; Dal Negro, Gianni; Delannois, Frédérique; Dent, Matt; Desaintes, Christian; Desprez, Bertrand; Dhalluin, Stephane; Hartmann, Andreas; Hoffmann-Doerr, Simone; Hubesch, Bruno; Irizar, Amaia; Manou, Irene; Müller, Boris P; Nadzialek, Stephanie; Prieto, Pilar; Rasenberg, Mike; Roggeband, Rob; Rowan, Tim G; Schutte, Katrin; van de Water, Bob; Westmoreland, Carl; Whelan, Maurice; Wilschut, Annette; Zvonimir, Zvonar; Cronin, Mark T D.
Afiliação
  • Laroche C; The International Fragrance Association (IFRA) Europe, Geneva, Switzerland; European Partnership for Alternative Approaches to Animal Testing (EPAA), Industry Secretariat, Belgium. Electronic address: charles.laroche@skynet.be.
  • Annys E; The European Chemical Industry Council (Cefic), Belgium. Electronic address: ean@cefic.be.
  • Bender H; Bonn, Germany. Electronic address: bender.hj@hotmail.de.
  • Botelho D; RIFM Research Institute for Fragrance Materials (RIFM) Inc., New Jersey, USA. Electronic address: dbotelho@rifm.org.
  • Botham P; Syngenta, Jealott's Hill, Bracknell, Berkshire, RG42 6EY, United Kingdom. Electronic address: phil.botham@syngenta.com.
  • Brendler-Schwaab S; Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175, Bonn, Germany. Electronic address: Susanne.Brendler-Schwaab@bfarm.de.
  • Clayton R; AnimalhealthEurope, Belgium. Electronic address: r.clayton@animalhealtheurope.eu.
  • Corvaro M; Corteva Agriscience, 3B Milton Park Square, Abingdon, Oxfordshire, OX14 4RN, United Kingdom. Electronic address: marco.corvaro@corteva.com.
  • Dal Negro G; GlaxoSmithKline, United Kingdom. Electronic address: gianni.a.dal-negro@gsk.com.
  • Delannois F; GlaxoSmithKline, United Kingdom. Electronic address: frederique.x.delannois@gsk.com.
  • Dent M; SEAC, Unilever, Colworth Science Park, Bedford, MK44 1LQ, United Kingdom. Electronic address: Matthew.dent@unilever.com.
  • Desaintes C; European Commission, The Directorate-General (DG) for Research and Innovation (RTD), Belgium. Electronic address: christian.desaintes@ec.europa.eu.
  • Desprez B; Cosmetics Europe - The Personal Care Association, Belgium. Electronic address: BDesprez@cosmeticseurope.eu.
  • Dhalluin S; L'Oréal Research & Innovation, France. Electronic address: stephane.dhalluin@rd.loreal.com.
  • Hartmann A; Novartis, Switzerland. Electronic address: andreas.hartmann@novartis.com.
  • Hoffmann-Doerr S; Henkel AG & Co KGaA, Germany. Electronic address: Simone.Hoffmann-Doerr@henkel.com.
  • Hubesch B; Hubesch Consult BVBA, Belgium. Electronic address: bhu@cefic.be.
  • Irizar A; The International Fragrance Association (IFRA) Europe, Geneva, Switzerland. Electronic address: airizar@ifraorg.org.
  • Manou I; European Partnership for Alternative Approaches to Animal Testing (EPAA), Industry Secretariat, Belgium. Electronic address: irene.manou@epaaind.eu.
  • Müller BP; Symrise AG, Mühlenfeldstr. 1, 37603, Holzminden, Germany. Electronic address: boris.mueller@symrise.com.
  • Nadzialek S; ECPA - the European Crop Protection Association, Belgium. Electronic address: stephanie.nadzialek@ecpa.eu.
  • Prieto P; European Commission, Joint Research Centre (JRC), Italy. Electronic address: Pilar.Prieto-Peraita@ec.europa.eu.
  • Rasenberg M; European Chemicals Agency (ECHA), Finland. Electronic address: Mike.RASENBERG@echa.europa.eu.
  • Roggeband R; Procter & Gamble Services NV/SA, Temselaan 100, 1853, Strombeek-Bever, Belgium. Electronic address: roggeband.r@pg.com.
  • Rowan TG; EPAA Consultant, Cawton, York, United Kingdom. Electronic address: tim_g_rowan@hotmail.com.
  • Schutte K; European Commission, The Directorate-General (DG) Environment (ENV), Belgium. Electronic address: Katrin.SCHUTTE@ec.europa.eu.
  • van de Water B; Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research (LACDR), Leiden University, the Netherlands. Electronic address: water_b@lacdr.leidenuniv.nl.
  • Westmoreland C; SEAC, Unilever, Colworth Science Park, Bedford, MK44 1LQ, United Kingdom. Electronic address: Carl.Westmoreland@unilever.com.
  • Whelan M; European Commission, Joint Research Centre (JRC), Italy. Electronic address: Maurice.WHELAN@ec.europa.eu.
  • Wilschut A; Royal DSM N.V., P.O. Box 6500, 6401 JH, Heerlen, the Netherlands. Electronic address: annette.wilschut@dsm.com.
  • Zvonimir Z; European Partnership for Alternative Approaches to Animal Testing (EPAA), Industry Secretariat, Belgium. Electronic address: zvonar.zvonimir@epaaind.eu.
  • Cronin MTD; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, United Kingdom. Electronic address: m.t.cronin@ljmu.ac.uk.
Regul Toxicol Pharmacol ; 108: 104470, 2019 Nov.
Article em En | MEDLINE | ID: mdl-31479718
ABSTRACT
The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a Partners' Forum on repeated dose toxicity (RDT) testing to identify synergies between industrial sectors and stakeholders along with opportunities to progress these in existing research frameworks. Although RTD testing is not performed across all industrial sectors, the OECD accepted tests can provide a rich source of information and play a pivotal role for safety decisions relating to the use of chemicals. Currently there are no validated alternatives to repeated dose testing and a direct one-to-one replacement is not appropriate. However, there are many projects and initiatives at the international level which aim to implement various aspects of replacement, reduction and refinement (the 3Rs) in RDT testing. Improved definition of use, through better problem formulation, aligned to harmonisation of regulations is a key area, as is the more rapid implementation of alternatives into the legislative framework. Existing test designs can be optimised to reduce animal use and increase information content. Greater use of exposure-led decisions and improvements in dose selection will be beneficial. In addition, EPAA facilitates sharing of case studies demonstrating the use of Next Generation Risk Assessment applying various New Approach Methodologies to assess RDT.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Toxicidade / Alternativas aos Testes com Animais Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Testes de Toxicidade / Alternativas aos Testes com Animais Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article